Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS ...

Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until ...